glp-1 obesity drug news oct 21 2025 New Pill Foundayo (Orforglipron) Gets FDA Approval for GLP-1s for Weight Loss: What

Taraschi F, Salgarello M

doi: 10.1016/j.lfs.2004.11.030

The OpenLoop telehealth consent form you sign during this process states that the assessment "does not create a doctor-patient relationship between the individual completing the assessment and LIV Body." If you're screened out at this stage, per the brand's stated process, your information won't be submitted to a provider and you'll need to seek care another way

[DOI] [PubMed] [Google Scholar] 20.Lau D.C.W., Erichsen L., Francisco A.M., et al

Continued efforts to improve real-world implementation will be essential to ensuring that GLP-1 RAs deliver meaningful clinical and public health benefits across a range of chronic conditions

AstraZeneca has agreed to pay CSPC $1.2 billion up front and up to $3.5 billion in development and regulatory milestone payments across eight drug development programs for weight loss and Type 2 diabetes, the British firm says in a Jan